uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.1300 | Q16 | What Small molecule therapies have been approved by the FDA to treat meibomian cyst? | There are no drug Small molecule therapies approved to treat meibomian cyst. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "meibomian cyst" OR LOWER(mesh_heading) = "meibomian cyst") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1226 | Q16 | What Small molecule therapies have been approved by the FDA to treat joint disease? | There are no drug Small molecule therapies approved to treat joint disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "joint disease" OR LOWER(mesh_heading) = "joint disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.174 | Q16 | What Protein therapies have been approved by the FDA to treat hip fracture? | There are no drug Protein therapies approved to treat hip fracture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hip fracture" OR LOWER(mesh_heading) = "hip fracture") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1701 | Q16 | What Small molecule therapies have been approved by the FDA to treat tonsil cancer? | There are no drug Small molecule therapies approved to treat tonsil cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tonsil cancer" OR LOWER(mesh_heading) = "tonsil cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1522 | Q16 | What Small molecule therapies have been approved by the FDA to treat primary biliary cirrhosis? | Obeticholic Acid is the only Small molecule therapy approved by the FDA to treat primary biliary cirrhosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary biliary cirrhosis" OR LOWER(mesh_heading) = "primary biliary cirrhosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104323', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104338', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104353', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104368', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104383', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104398', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104413', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104428', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104443', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104458', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104473', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104488', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104503', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104518', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104533', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104548', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104563', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104578', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104593', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104608', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'primary biliary cirrhosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.77 | Q16 | What Protein therapies have been approved by the FDA to treat acromegaly? | There are 2 Protein therapy drugs that are approved to treat acromegaly which are as follows: Pasireotide Pamoate and Octreotide Acetate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acromegaly" OR LOWER(mesh_heading) = "acromegaly") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1041094', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041095', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041096', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041097', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041098', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041099', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041100', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041101', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041102', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041103', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041104', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041105', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041106', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041107', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041108', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041109', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041110', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041111', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041112', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041113', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041114', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041115', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041116', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041117', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041118', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041119', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041120', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041121', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041122', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041123', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041124', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041125', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041126', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041127', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041128', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041129', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041130', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041131', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041132', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041133', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041134', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041135', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041136', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041137', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041138', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041139', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041140', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041141', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041142', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041143', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041144', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041145', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041146', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041147', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041148', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041149', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041150', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041151', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041152', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041153', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041154', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041155', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041156', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041157', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041158', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041159', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041160', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041161', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041162', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041163', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041164', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1041165', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042020', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042041', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042062', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042083', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042104', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042125', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042146', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042167', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042188', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042209', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042230', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042251', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042272', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042293', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042314', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042335', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042356', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042377', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042398', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042419', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042440', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042461', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042482', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042503', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042524', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042545', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042566', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_1042587', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1762 | Q16 | What Small molecule therapies have been approved by the FDA to treat wheezing? | There are no drug Small molecule therapies approved to treat wheezing. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "wheezing" OR LOWER(mesh_heading) = "wheezing") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.414 | Q16 | What Small molecule therapies have been approved by the FDA to treat Dravet syndrome? | There are 2 Small molecule therapy drugs that are approved to treat Dravet syndrome which are as follows: Fenfluramine Hydrochloride and Cannabidiol. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dravet syndrome" OR LOWER(mesh_heading) = "dravet syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155511', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155514', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155517', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155520', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155523', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155526', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155529', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155532', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155535', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155538', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155541', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155544', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155547', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155550', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155553', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155556', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155559', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155562', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155565', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155568', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155571', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155574', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155577', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155580', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155583', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155586', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155589', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155592', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155595', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155598', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155601', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155604', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155607', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155610', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155613', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155616', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155619', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155622', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155625', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155628', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155631', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155634', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155637', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155640', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155643', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155646', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155649', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155652', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155655', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155658', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155661', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155664', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155667', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155670', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000179546', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155673', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155676', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155679', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155682', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155685', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155688', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155691', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155694', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155697', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155700', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155703', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155706', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155709', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155712', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155715', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155718', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155721', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155724', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155727', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155730', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155733', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155736', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155739', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155742', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155745', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155748', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_155751', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147955', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073400', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073473', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073546', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073619', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073692', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073765', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073838', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073911', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1073984', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074057', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074130', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074203', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074276', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074349', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074422', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074495', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074568', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074641', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1074714', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1105 | Q16 | What Small molecule therapies have been approved by the FDA to treat germ cell tumor? | There are no drug Small molecule therapies approved to treat germ cell tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "germ cell tumor" OR LOWER(mesh_heading) = "germ cell tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1510 | Q16 | What Small molecule therapies have been approved by the FDA to treat postpartum hemorrhage? | There are no drug Small molecule therapies approved to treat postpartum hemorrhage. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "postpartum hemorrhage" OR LOWER(mesh_heading) = "postpartum hemorrhage") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1140 | Q16 | What Small molecule therapies have been approved by the FDA to treat hemorrhagic fever with renal syndrome? | There are no drug Small molecule therapies approved to treat hemorrhagic fever with renal syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemorrhagic fever with renal syndrome" OR LOWER(mesh_heading) = "hemorrhagic fever with renal syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.981 | Q16 | What Small molecule therapies have been approved by the FDA to treat dermatofibrosarcoma protuberans? | There are no drug Small molecule therapies approved to treat dermatofibrosarcoma protuberans. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dermatofibrosarcoma protuberans" OR LOWER(mesh_heading) = "dermatofibrosarcoma protuberans") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1706 | Q16 | What Small molecule therapies have been approved by the FDA to treat transposition of the great arteries? | There are no drug Small molecule therapies approved to treat transposition of the great arteries. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "transposition of the great arteries" OR LOWER(mesh_heading) = "transposition of the great arteries") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.31 | Q16 | What Protein therapies have been approved by the FDA to treat Central diabetes insipidus? | Desmopressin Acetate is the only Protein therapy approved by the FDA to treat Central diabetes insipidus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "central diabetes insipidus" OR LOWER(mesh_heading) = "central diabetes insipidus") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694395', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694406', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694417', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694428', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694439', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694450', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694461', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694472', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694483', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694494', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694505', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694516', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694527', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694538', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694549', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694560', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694571', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694582', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694593', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694604', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694615', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694626', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694637', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694648', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694659', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694670', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694681', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694692', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694703', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694714', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694725', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694736', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694747', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694758', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694769', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694780', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694791', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694802', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694813', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694824', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694835', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694846', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694857', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694868', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694879', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694890', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694901', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694912', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694923', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694934', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694945', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694956', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694967', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694978', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694989', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695000', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695011', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695022', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695033', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695044', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695055', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695066', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_695077', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1119 | Q16 | What Small molecule therapies have been approved by the FDA to treat hairy cell leukemia? | There are no drug Small molecule therapies approved to treat hairy cell leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hairy cell leukemia" OR LOWER(mesh_heading) = "hairy cell leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.992 | Q16 | What Small molecule therapies have been approved by the FDA to treat diastolic heart failure? | There are no drug Small molecule therapies approved to treat diastolic heart failure. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diastolic heart failure" OR LOWER(mesh_heading) = "diastolic heart failure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.623 | Q16 | What Small molecule therapies have been approved by the FDA to treat Shoulder pain? | There are no drug Small molecule therapies approved to treat Shoulder pain. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "shoulder pain" OR LOWER(mesh_heading) = "shoulder pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.333 | Q16 | What Small molecule therapies have been approved by the FDA to treat Adenoma sebaceum? | Everolimus is the only Small molecule therapy approved by the FDA to treat Adenoma sebaceum. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adenoma sebaceum" OR LOWER(mesh_heading) = "adenoma sebaceum") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084952', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1085087', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1085222', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1085357', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1085492', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1085627', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1085762', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1085897', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086032', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086167', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086302', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086437', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086572', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086707', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086842', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1086977', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1087112', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1087247', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1087382', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1087517', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1087652', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1087787', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1087922', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1088057', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1088192', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1088327', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1088462', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1088597', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1088732', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1088867', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089002', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089137', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089272', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089407', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089542', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089677', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089812', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1089947', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1090082', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1090217', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1090352', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1090487', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}, {'UUID': 'DrugTargetsIndication121923_text_1090622', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1365 | Q16 | What Small molecule therapies have been approved by the FDA to treat nephrogenic fibrosing dermopathy? | There are no drug Small molecule therapies approved to treat nephrogenic fibrosing dermopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nephrogenic fibrosing dermopathy" OR LOWER(mesh_heading) = "nephrogenic fibrosing dermopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.100 | Q16 | What Protein therapies have been approved by the FDA to treat autism spectrum disorder? | There are no drug Protein therapies approved to treat autism spectrum disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "autism spectrum disorder" OR LOWER(mesh_heading) = "autism spectrum disorder") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.767 | Q16 | What Small molecule therapies have been approved by the FDA to treat angiosarcoma? | There are no drug Small molecule therapies approved to treat angiosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "angiosarcoma" OR LOWER(mesh_heading) = "angiosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1143 | Q16 | What Small molecule therapies have been approved by the FDA to treat hepatitis C virus infection? | There are no drug Small molecule therapies approved to treat hepatitis C virus infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatitis c virus infection" OR LOWER(mesh_heading) = "hepatitis c virus infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1373 | Q16 | What Small molecule therapies have been approved by the FDA to treat neuroendocrine neoplasm? | Everolimus is the only Small molecule therapy approved by the FDA to treat neuroendocrine neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroendocrine neoplasm" OR LOWER(mesh_heading) = "neuroendocrine neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084966', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1085101', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1085236', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1085371', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1085506', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1085641', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1085776', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1085911', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086046', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086181', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086316', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086451', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086586', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086721', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086856', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1086991', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1087126', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1087261', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1087396', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1087531', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1087666', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1087801', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1087936', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1088071', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1088206', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1088341', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1088476', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1088611', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1088746', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1088881', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089016', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089151', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089286', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089421', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089556', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089691', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089826', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1089961', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1090096', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1090231', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1090366', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1090501', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_1090636', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.957 | Q16 | What Small molecule therapies have been approved by the FDA to treat contact dermatitis? | There are 2 Small molecule therapy drugs that are approved to treat contact dermatitis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "contact dermatitis" OR LOWER(mesh_heading) = "contact dermatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217647', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_217855', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218063', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218271', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218479', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218687', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218895', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219103', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219311', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219519', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219727', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219935', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220143', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220351', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220559', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220767', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226343', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226628', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226913', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227198', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227483', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227768', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228053', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228338', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228623', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228908', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229193', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229478', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229763', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230048', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230333', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230618', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230903', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231188', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231473', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231758', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_232043', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_232328', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.909 | Q16 | What Small molecule therapies have been approved by the FDA to treat chromophobe renal cell carcinoma? | There are 2 Small molecule therapy drugs that are approved to treat chromophobe renal cell carcinoma which are as follows: Pazopanib Hydrochloride and Sorafenib Tosylate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chromophobe renal cell carcinoma" OR LOWER(mesh_heading) = "chromophobe renal cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_667822', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667850', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667878', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667906', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667934', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667962', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667990', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668018', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668046', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668074', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668102', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668130', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668158', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668186', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668214', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668242', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668270', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668298', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668326', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668354', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668382', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668410', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683231', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683292', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683353', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683414', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683475', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683536', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683597', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683658', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683719', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683780', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683841', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683902', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_683963', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684024', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684085', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684146', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684207', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684268', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684329', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684390', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684451', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684512', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684573', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684634', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684695', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684756', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684817', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684878', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_684939', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685000', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685061', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685122', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685183', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685244', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685305', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685366', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685427', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685488', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685549', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685610', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685671', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685732', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685793', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685854', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_685915', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1583 | Q16 | What Small molecule therapies have been approved by the FDA to treat retinoblastoma? | There are no drug Small molecule therapies approved to treat retinoblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "retinoblastoma" OR LOWER(mesh_heading) = "retinoblastoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1182 | Q16 | What Small molecule therapies have been approved by the FDA to treat idiopathic hypersomnia? | There are no drug Small molecule therapies approved to treat idiopathic hypersomnia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "idiopathic hypersomnia" OR LOWER(mesh_heading) = "idiopathic hypersomnia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.682 | Q16 | What Small molecule therapies have been approved by the FDA to treat Weight loss? | There are no drug Small molecule therapies approved to treat Weight loss. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "weight loss" OR LOWER(mesh_heading) = "weight loss") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1691 | Q16 | What Small molecule therapies have been approved by the FDA to treat thrombotic thrombocytopenic purpura? | There are no drug Small molecule therapies approved to treat thrombotic thrombocytopenic purpura. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombotic thrombocytopenic purpura" OR LOWER(mesh_heading) = "thrombotic thrombocytopenic purpura") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.442 | Q16 | What Small molecule therapies have been approved by the FDA to treat Fatigue? | There are no drug Small molecule therapies approved to treat Fatigue. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fatigue" OR LOWER(mesh_heading) = "fatigue") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1255 | Q16 | What Small molecule therapies have been approved by the FDA to treat liposarcoma? | There are no drug Small molecule therapies approved to treat liposarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "liposarcoma" OR LOWER(mesh_heading) = "liposarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1064 | Q16 | What Small molecule therapies have been approved by the FDA to treat fecal incontinence? | There are no drug Small molecule therapies approved to treat fecal incontinence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fecal incontinence" OR LOWER(mesh_heading) = "fecal incontinence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.900 | Q16 | What Small molecule therapies have been approved by the FDA to treat cholestasis? | There are no drug Small molecule therapies approved to treat cholestasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cholestasis" OR LOWER(mesh_heading) = "cholestasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.33 | Q16 | What Protein therapies have been approved by the FDA to treat Cognitive impairment? | There are no drug Protein therapies approved to treat Cognitive impairment. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cognitive impairment" OR LOWER(mesh_heading) = "cognitive impairment") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1759 | Q16 | What Small molecule therapies have been approved by the FDA to treat vulva cancer? | There are no drug Small molecule therapies approved to treat vulva cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vulva cancer" OR LOWER(mesh_heading) = "vulva cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1205 | Q16 | What Small molecule therapies have been approved by the FDA to treat internal carotid artery stenosis? | There are no drug Small molecule therapies approved to treat internal carotid artery stenosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "internal carotid artery stenosis" OR LOWER(mesh_heading) = "internal carotid artery stenosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.222 | Q16 | What Protein therapies have been approved by the FDA to treat morbid obesity? | There are no drug Protein therapies approved to treat morbid obesity. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "morbid obesity" OR LOWER(mesh_heading) = "morbid obesity") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.189 | Q16 | What Protein therapies have been approved by the FDA to treat invasive lobular carcinoma? | There are no drug Protein therapies approved to treat invasive lobular carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "invasive lobular carcinoma" OR LOWER(mesh_heading) = "invasive lobular carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.895 | Q16 | What Small molecule therapies have been approved by the FDA to treat childhood apraxia of speech? | There are no drug Small molecule therapies approved to treat childhood apraxia of speech. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "childhood apraxia of speech" OR LOWER(mesh_heading) = "childhood apraxia of speech") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.384 | Q16 | What Small molecule therapies have been approved by the FDA to treat Chemotherapy-induced nausea and vomiting? | There are 7 Small molecule therapy drugs that are approved to treat Chemotherapy-induced nausea and vomiting which are as follows: Palonosetron Hydrochloride, Granisetron, Ondansetron, Aprepitant, Rolapitant Hydrochloride, Fosaprepitant Dimeglumine, and Dronabinol. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chemotherapy-induced nausea and vomiting" OR LOWER(mesh_heading) = "chemotherapy-induced nausea and vomiting") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205494', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205500', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205506', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205512', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205518', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205524', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205530', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205536', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205542', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205548', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205554', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205560', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205566', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205572', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205578', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205584', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205590', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205596', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205602', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205608', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205614', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205620', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205626', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205632', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205638', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205644', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205650', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205656', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205662', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205668', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205674', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205680', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205686', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205692', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205698', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205704', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205710', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205716', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205722', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205728', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205734', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205740', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205753', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205754', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205767', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205768', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205781', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205782', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205795', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205796', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205809', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205810', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205823', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205824', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205861', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205862', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205901', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205902', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205941', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205942', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205981', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205982', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072760', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072761', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072783', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072784', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072806', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072807', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072829', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072830', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072852', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072853', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072875', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072876', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072898', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072899', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072921', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072922', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072944', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072945', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072967', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072968', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072990', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1072991', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073013', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073014', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073036', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073037', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073059', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073060', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073082', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073083', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073105', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073106', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073108', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073109', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073111', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073112', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073114', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_1073115', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000115353', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.487 | Q16 | What Small molecule therapies have been approved by the FDA to treat Herpes Labialis? | Hydrocortisone is the only Small molecule therapy approved by the FDA to treat Herpes Labialis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "herpes labialis" OR LOWER(mesh_heading) = "herpes labialis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_240818', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_240900', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_240982', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241064', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241146', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241228', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241310', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241392', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241474', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241556', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241638', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241720', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241802', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}, {'UUID': 'DrugTargetsIndication121923_text_241884', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.945 | Q16 | What Small molecule therapies have been approved by the FDA to treat colorectal carcinoma? | Regorafenib is the only Small molecule therapy approved by the FDA to treat colorectal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colorectal carcinoma" OR LOWER(mesh_heading) = "colorectal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_664068', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664104', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664140', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664176', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664212', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664248', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664284', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664320', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664356', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664392', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664428', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664464', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664500', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664536', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664572', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664608', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664644', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664680', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664716', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664752', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664788', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664824', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664860', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664896', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664932', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664968', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665004', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665040', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665076', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665112', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665148', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665184', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665220', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665256', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665292', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665328', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665364', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665400', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665436', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665472', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665508', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665544', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665580', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665616', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665652', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665688', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665724', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665760', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665796', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665832', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665868', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665904', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665940', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665976', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666012', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666048', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666084', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666120', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666156', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666192', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666228', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666264', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666300', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666336', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666372', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666408', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666444', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666480', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666516', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666552', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666588', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666624', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666660', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666696', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666732', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666768', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666804', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666840', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666876', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666912', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666948', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666984', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667020', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667056', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667092', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667128', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667164', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667200', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667236', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667272', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.475 | Q16 | What Small molecule therapies have been approved by the FDA to treat Heat Stroke? | There are no drug Small molecule therapies approved to treat Heat Stroke. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "heat stroke" OR LOWER(mesh_heading) = "heat stroke") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.45 | Q16 | What Protein therapies have been approved by the FDA to treat Hyperglycemia? | There are no drug Protein therapies approved to treat Hyperglycemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperglycemia" OR LOWER(mesh_heading) = "hyperglycemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1460 | Q16 | What Small molecule therapies have been approved by the FDA to treat pericarditis? | There are no drug Small molecule therapies approved to treat pericarditis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pericarditis" OR LOWER(mesh_heading) = "pericarditis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.559 | Q16 | What Small molecule therapies have been approved by the FDA to treat Myocardial Ischemia? | There are no drug Small molecule therapies approved to treat Myocardial Ischemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myocardial ischemia" OR LOWER(mesh_heading) = "myocardial ischemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.354 | Q16 | What Small molecule therapies have been approved by the FDA to treat B-Cell Prolymphocytic Leukemia? | There are no drug Small molecule therapies approved to treat B-Cell Prolymphocytic Leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "b-cell prolymphocytic leukemia" OR LOWER(mesh_heading) = "b-cell prolymphocytic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.867 | Q16 | What Small molecule therapies have been approved by the FDA to treat cardiac arrhythmia? | There are 2 Small molecule therapy drugs that are approved to treat cardiac arrhythmia which are as follows: Lidocaine and Propranolol Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cardiac arrhythmia" OR LOWER(mesh_heading) = "cardiac arrhythmia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637785', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_637900', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638015', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638130', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638245', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638360', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638475', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638590', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638705', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638820', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638935', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639050', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639165', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639280', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639395', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639510', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639625', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639740', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639855', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639970', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640085', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640200', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640315', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640430', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640545', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640660', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640775', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640890', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641005', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641120', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641235', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641350', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641465', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641580', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641695', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641810', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641925', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642040', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642155', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642270', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642385', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642500', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642615', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642730', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642845', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642960', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643075', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643190', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643305', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643420', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643535', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643650', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643765', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643880', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643995', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644110', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644225', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644340', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644455', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644570', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_937020', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_937043', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_937066', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_937089', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.324 | Q16 | What Small molecule therapies have been approved by the FDA to treat Abdominal pain? | There are no drug Small molecule therapies approved to treat Abdominal pain. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abdominal pain" OR LOWER(mesh_heading) = "abdominal pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.60 | Q16 | What Protein therapies have been approved by the FDA to treat Recurrent thrombophlebitis? | Bivalirudin is the only Protein therapy approved by the FDA to treat Recurrent thrombophlebitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "recurrent thrombophlebitis" OR LOWER(mesh_heading) = "recurrent thrombophlebitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092311', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_1092328', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_1092345', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_1092362', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1197 | Q16 | What Small molecule therapies have been approved by the FDA to treat influenza? | There are 3 Small molecule therapy drugs that are approved to treat influenza which are as follows: Amantadine Hydrochloride, Acetaminophen, and Ibuprofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "influenza" OR LOWER(mesh_heading) = "influenza") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_441020', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441034', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441048', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441062', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441076', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441090', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441104', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441118', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441132', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441146', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441160', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441174', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441188', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441202', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441216', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441230', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441244', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441258', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441272', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441286', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441300', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441314', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441328', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441342', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441356', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441370', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441384', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441398', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441412', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441426', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441440', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441454', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441468', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441482', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441496', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441510', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441524', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441538', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441552', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441566', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441580', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441594', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441608', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441622', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441636', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441650', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441664', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441678', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441692', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441706', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441720', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441734', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441748', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441762', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441776', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441790', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441804', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441818', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441832', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441846', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441860', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441874', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441888', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441902', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441916', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441930', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441944', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441958', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441972', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_441986', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442000', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442014', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442028', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442042', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442056', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442070', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442084', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442098', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442112', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442126', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442140', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442154', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442168', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442182', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442196', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442210', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442224', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442238', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442252', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442266', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442280', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442294', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442308', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442322', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442336', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442350', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442364', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442378', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442392', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}, {'UUID': 'DrugTargetsIndication121923_text_442406', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.498 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hypercholesterolemia? | There are 7 Small molecule therapy drugs that are approved to treat Hypercholesterolemia which are as follows: Fenofibric Acid, Fenofibrate, Lomitapide Mesylate, Amlodipine Besylate, Ezetimibe, Simvastatin, and Rosuvastatin Calcium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypercholesterolemia" OR LOWER(mesh_heading) = "hypercholesterolemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243812', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243818', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243824', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243830', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243836', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243842', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243848', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243854', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243860', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243866', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243872', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243878', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243884', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243890', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243896', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243902', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243938', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243967', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_243996', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244025', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244054', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244083', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244112', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244141', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244170', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244199', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244228', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244257', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244286', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244315', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244344', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244373', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244402', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_244431', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042946', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042950', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042954', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042958', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042962', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042966', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042970', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042974', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042978', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042982', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042986', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042990', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042994', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042998', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043002', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043006', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043010', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043014', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043018', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043022', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043026', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043030', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043034', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043038', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043042', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043046', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043050', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043054', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043058', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043062', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043066', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043070', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043074', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043078', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043082', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043086', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043090', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043094', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043098', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043102', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043106', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043110', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043114', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043118', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043122', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043126', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043130', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043134', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043138', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043142', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043146', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043150', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043154', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043158', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043162', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043166', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043170', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043174', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043178', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043182', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043186', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043190', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043194', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043198', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043202', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043206', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.773 | Q16 | What Small molecule therapies have been approved by the FDA to treat anterior uveitis? | Loteprednol Etabonate is the only Small molecule therapy approved by the FDA to treat anterior uveitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anterior uveitis" OR LOWER(mesh_heading) = "anterior uveitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225416', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225424', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225432', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225440', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225448', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225456', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225464', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225472', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225480', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225488', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225496', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225504', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225512', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225520', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225528', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225536', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225544', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225552', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225560', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225568', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225576', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225584', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225592', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225600', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_225608', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1538 | Q16 | What Small molecule therapies have been approved by the FDA to treat prostate cancer? | There are 7 Small molecule therapy drugs that are approved to treat prostate cancer which are as follows: Cabazitaxel, Enzalutamide, Apalutamide, Darolutamide, Lutetium Lu 177 Vipivotide Tetraxetan, Abiraterone Acetate, and Zoledronic Acid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostate cancer" OR LOWER(mesh_heading) = "prostate cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_67884', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_67908', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_67932', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_67956', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_67980', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68004', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68028', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68052', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68076', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68100', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68124', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68148', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68172', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68196', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68220', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68244', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68268', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68292', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68316', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68340', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68364', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68388', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68412', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68436', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68460', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68484', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68508', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68532', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68556', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68580', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68604', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68628', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68652', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68676', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68700', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68724', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68748', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68772', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68796', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68820', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68844', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68868', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68892', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68916', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68940', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68964', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_68988', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69012', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69036', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69060', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69084', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69108', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69132', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69156', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69180', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69204', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69228', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69252', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69276', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69300', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69324', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69348', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69372', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69396', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69420', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69444', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69468', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69492', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69516', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69540', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69564', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69588', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69612', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69636', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69660', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69684', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69708', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69732', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69756', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69780', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69804', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69828', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69852', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69876', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69900', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69924', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69948', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69972', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_69996', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_70020', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921033', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921052', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921071', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921090', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921109', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921128', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921147', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921166', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921185', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_921204', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1559 | Q16 | What Small molecule therapies have been approved by the FDA to treat radiodermatitis? | There are no drug Small molecule therapies approved to treat radiodermatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "radiodermatitis" OR LOWER(mesh_heading) = "radiodermatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1711 | Q16 | What Small molecule therapies have been approved by the FDA to treat tropical spastic paraparesis? | There are no drug Small molecule therapies approved to treat tropical spastic paraparesis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tropical spastic paraparesis" OR LOWER(mesh_heading) = "tropical spastic paraparesis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1562 | Q16 | What Small molecule therapies have been approved by the FDA to treat rectal carcinoma? | There are no drug Small molecule therapies approved to treat rectal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rectal carcinoma" OR LOWER(mesh_heading) = "rectal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.124 | Q16 | What Protein therapies have been approved by the FDA to treat chronic granulomatous disease? | There are no drug Protein therapies approved to treat chronic granulomatous disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic granulomatous disease" OR LOWER(mesh_heading) = "chronic granulomatous disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.370 | Q16 | What Small molecule therapies have been approved by the FDA to treat Bronchiolitis? | There are no drug Small molecule therapies approved to treat Bronchiolitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bronchiolitis" OR LOWER(mesh_heading) = "bronchiolitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1249 | Q16 | What Small molecule therapies have been approved by the FDA to treat leptospirosis? | There are no drug Small molecule therapies approved to treat leptospirosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "leptospirosis" OR LOWER(mesh_heading) = "leptospirosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.318 | Q16 | What Protein therapies have been approved by the FDA to treat von Willebrand disease (hereditary or acquired)? | Desmopressin Acetate is the only Protein therapy approved by the FDA to treat von Willebrand disease (hereditary or acquired). | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "von willebrand disease (hereditary or acquired)" OR LOWER(mesh_heading) = "von willebrand disease (hereditary or acquired)") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694401', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694412', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694423', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694434', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694445', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694456', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694467', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694478', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694489', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694500', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694511', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694522', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694533', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694544', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694555', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694566', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694577', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694588', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694599', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694610', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694621', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694632', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694643', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694654', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694665', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694676', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694687', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694698', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694709', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694720', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694731', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694742', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694753', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694764', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694775', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694786', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694797', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694808', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694819', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694830', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694841', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694852', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694863', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694874', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694885', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694896', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694907', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694918', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694929', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694940', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694951', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694962', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694973', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694984', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_694995', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695006', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695017', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695028', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695039', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695050', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695061', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695072', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}, {'UUID': 'DrugTargetsIndication121923_text_695083', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1126 | Q16 | What Small molecule therapies have been approved by the FDA to treat hearing loss? | There are no drug Small molecule therapies approved to treat hearing loss. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hearing loss" OR LOWER(mesh_heading) = "hearing loss") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.483 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hepatoblastoma? | There are no drug Small molecule therapies approved to treat Hepatoblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatoblastoma" OR LOWER(mesh_heading) = "hepatoblastoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1015 | Q16 | What Small molecule therapies have been approved by the FDA to treat embryonal rhabdomyosarcoma? | There are no drug Small molecule therapies approved to treat embryonal rhabdomyosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "embryonal rhabdomyosarcoma" OR LOWER(mesh_heading) = "embryonal rhabdomyosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1525 | Q16 | What Small molecule therapies have been approved by the FDA to treat primary erythermalgia? | There are no drug Small molecule therapies approved to treat primary erythermalgia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary erythermalgia" OR LOWER(mesh_heading) = "primary erythermalgia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1319 | Q16 | What Small molecule therapies have been approved by the FDA to treat methamphetamine dependence? | There are no drug Small molecule therapies approved to treat methamphetamine dependence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "methamphetamine dependence" OR LOWER(mesh_heading) = "methamphetamine dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1042 | Q16 | What Small molecule therapies have been approved by the FDA to treat esophageal varices? | There are no drug Small molecule therapies approved to treat esophageal varices. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "esophageal varices" OR LOWER(mesh_heading) = "esophageal varices") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.300 | Q16 | What Protein therapies have been approved by the FDA to treat subarachnoid hemorrhage? | There are no drug Protein therapies approved to treat subarachnoid hemorrhage. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "subarachnoid hemorrhage" OR LOWER(mesh_heading) = "subarachnoid hemorrhage") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1347 | Q16 | What Small molecule therapies have been approved by the FDA to treat mycosis fungoides? | There are 3 Small molecule therapy drugs that are approved to treat mycosis fungoides which are as follows: Prednisone, Dexamethasone, and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mycosis fungoides" OR LOWER(mesh_heading) = "mycosis fungoides") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217670', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_217878', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_218086', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_218294', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_218502', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_218710', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_218918', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_219126', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_219334', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_219542', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_219750', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_219958', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_220166', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_220374', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_220582', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_220790', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_226367', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_226652', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_226937', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_227222', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_227507', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_227792', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_228077', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_228362', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_228647', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_228932', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_229217', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_229502', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_229787', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_230072', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_230357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_230642', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_230927', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_231212', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_231497', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_231782', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_232067', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_232352', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1056791', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1056952', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1057113', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1057274', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1057435', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1057596', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1057757', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1057918', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1058079', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1058240', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1058401', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1058562', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1058723', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1058884', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1059045', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1059206', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1059367', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1059528', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1059689', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1059850', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1060011', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1060172', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1060333', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1060494', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1060655', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1060816', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1060977', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1061138', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1061299', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1061460', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1061621', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1061782', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1061943', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1062104', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1062265', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1062426', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1062587', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1062748', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1062909', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1063070', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1063231', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1063392', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1063553', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1063714', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1063875', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1064036', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1064197', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1064358', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1064519', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1064680', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1064841', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1065002', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1065163', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1065324', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1065485', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1065646', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1065807', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1065968', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1066129', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1066290', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1066451', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}, {'UUID': 'DrugTargetsIndication121923_text_1066612', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1751 | Q16 | What Small molecule therapies have been approved by the FDA to treat verrucous carcinoma? | There are no drug Small molecule therapies approved to treat verrucous carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "verrucous carcinoma" OR LOWER(mesh_heading) = "verrucous carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1331 | Q16 | What Small molecule therapies have been approved by the FDA to treat morbid obesity? | There are no drug Small molecule therapies approved to treat morbid obesity. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "morbid obesity" OR LOWER(mesh_heading) = "morbid obesity") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.241 | Q16 | What Protein therapies have been approved by the FDA to treat non-alcoholic fatty liver disease? | There are no drug Protein therapies approved to treat non-alcoholic fatty liver disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "non-alcoholic fatty liver disease" OR LOWER(mesh_heading) = "non-alcoholic fatty liver disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.851 | Q16 | What Small molecule therapies have been approved by the FDA to treat bronchoalveolar adenocarcinoma? | There are no drug Small molecule therapies approved to treat bronchoalveolar adenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bronchoalveolar adenocarcinoma" OR LOWER(mesh_heading) = "bronchoalveolar adenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1557 | Q16 | What Small molecule therapies have been approved by the FDA to treat pustulosis palmaris et plantaris? | Apremilast is the only Small molecule therapy approved by the FDA to treat pustulosis palmaris et plantaris. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pustulosis palmaris et plantaris" OR LOWER(mesh_heading) = "pustulosis palmaris et plantaris") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696795', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_696823', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_696851', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_696879', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_696907', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_696935', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_696963', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_696991', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697019', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697047', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697075', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697103', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697131', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697159', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697187', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697215', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697243', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697271', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697299', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697327', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697355', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697383', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697411', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697439', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697467', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697495', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697523', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697551', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697579', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697607', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697635', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697663', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697691', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697719', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697747', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697775', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697803', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697831', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697859', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697887', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697915', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697943', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697971', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_697999', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698027', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698055', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698083', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698111', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698139', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698167', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698195', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698223', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698251', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698279', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698307', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698335', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698363', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698391', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698419', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698447', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698475', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698503', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698531', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698559', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698587', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698615', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698643', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698671', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698699', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698727', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698755', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698783', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698811', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698839', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698867', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698895', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698923', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698951', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_698979', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699007', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699035', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699063', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699091', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699119', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699147', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699175', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699203', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699231', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699259', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699287', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699315', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699343', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699371', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699399', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699427', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699455', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699483', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699511', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699539', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}, {'UUID': 'DrugTargetsIndication121923_text_699567', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1061 | Q16 | What Small molecule therapies have been approved by the FDA to treat familial intrahepatic cholestasis? | Odevixibat is the only Small molecule therapy approved by the FDA to treat familial intrahepatic cholestasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial intrahepatic cholestasis" OR LOWER(mesh_heading) = "familial intrahepatic cholestasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_992712', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992719', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992726', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992733', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992740', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992747', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992754', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992761', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992768', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992775', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992782', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992789', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992796', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992803', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992810', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992817', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992824', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992831', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992838', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992845', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992852', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992859', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992866', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992873', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992880', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992887', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992894', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992901', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992908', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992915', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992922', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992929', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992936', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992943', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992950', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992957', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992964', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992971', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992978', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992985', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992992', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_992999', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_993006', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}, {'UUID': 'DrugTargetsIndication121923_text_993013', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1164 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypersomnia? | Pitolisant Hydrochloride is the only Small molecule therapy approved by the FDA to treat hypersomnia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypersomnia" OR LOWER(mesh_heading) = "hypersomnia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828123', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828125', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828127', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828129', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828131', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828133', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828135', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828137', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828139', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}, {'UUID': 'DrugTargetsIndication121923_text_828141', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000101180', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1699 | Q16 | What Small molecule therapies have been approved by the FDA to treat tinea pedis? | There are no drug Small molecule therapies approved to treat tinea pedis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tinea pedis" OR LOWER(mesh_heading) = "tinea pedis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.369 | Q16 | What Small molecule therapies have been approved by the FDA to treat Bronchiectasis? | There are no drug Small molecule therapies approved to treat Bronchiectasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bronchiectasis" OR LOWER(mesh_heading) = "bronchiectasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.548 | Q16 | What Small molecule therapies have been approved by the FDA to treat Miosis? | There are no drug Small molecule therapies approved to treat Miosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "miosis" OR LOWER(mesh_heading) = "miosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.68 | Q16 | What Protein therapies have been approved by the FDA to treat T-cell large granular lymphocyte leukemia? | There are no drug Protein therapies approved to treat T-cell large granular lymphocyte leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "t-cell large granular lymphocyte leukemia" OR LOWER(mesh_heading) = "t-cell large granular lymphocyte leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1115 | Q16 | What Small molecule therapies have been approved by the FDA to treat gout? | There are 8 Small molecule therapy drugs that are approved to treat gout which are as follows: Colchicine, Prednisone, Triamcinolone Acetonide, Indomethacin, Naproxen Sodium, Naproxen, Febuxostat, and Lesinurad. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gout" OR LOWER(mesh_heading) = "gout") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_70057', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70095', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70133', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70171', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70209', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70247', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70285', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70323', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70361', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70399', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70437', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70475', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70513', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70551', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70589', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70627', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70665', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70703', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70741', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70779', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70817', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70855', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70893', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70931', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_70969', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71007', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71045', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71083', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71121', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71159', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71197', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71235', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71273', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71311', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71349', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71387', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71425', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71463', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71501', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71539', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71577', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71615', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71653', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71691', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71729', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71767', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71805', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71843', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71881', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71919', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71957', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_71995', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72033', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72071', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72109', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72147', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72185', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72223', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72261', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72299', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72337', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72375', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72413', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72451', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72489', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72527', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72565', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72603', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72641', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72679', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72717', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72755', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72793', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72831', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72869', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72907', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72945', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_72983', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73021', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73059', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73097', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73135', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73173', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73211', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73249', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73287', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73325', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73363', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73401', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73439', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73477', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73515', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73553', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73591', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73629', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73667', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73705', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73743', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73781', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}, {'UUID': 'DrugTargetsIndication121923_text_73819', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.810 | Q16 | What Small molecule therapies have been approved by the FDA to treat bacterial sexually transmitted disease? | There are no drug Small molecule therapies approved to treat bacterial sexually transmitted disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bacterial sexually transmitted disease" OR LOWER(mesh_heading) = "bacterial sexually transmitted disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.125 | Q16 | What Protein therapies have been approved by the FDA to treat chronic hepatitis C virus infection? | There are no drug Protein therapies approved to treat chronic hepatitis C virus infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic hepatitis c virus infection" OR LOWER(mesh_heading) = "chronic hepatitis c virus infection") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.761 | Q16 | What Small molecule therapies have been approved by the FDA to treat anemia (phenotype)? | Lenalidomide is the only Small molecule therapy approved by the FDA to treat anemia (phenotype). | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anemia (phenotype)" OR LOWER(mesh_heading) = "anemia (phenotype)") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1105737', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1105824', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1105911', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1105998', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106085', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106172', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106259', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106346', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106433', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106520', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106607', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106694', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106781', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106868', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106955', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107042', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107129', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107216', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107303', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107390', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107477', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107564', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107651', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107738', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107825', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107912', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107999', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108086', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108173', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108260', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108347', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108434', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108521', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108608', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108695', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108782', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108869', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108956', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109043', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109130', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109217', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109304', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109391', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109478', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109565', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109652', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109739', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109826', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109913', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110000', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110087', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110174', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110261', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110348', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110435', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110522', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110609', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110696', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110783', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110870', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1110957', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111044', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111131', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111218', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111305', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111392', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111479', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111566', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111653', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111740', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111827', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1111914', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112001', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112088', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112175', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112262', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112349', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112436', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112523', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112610', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112697', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112784', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112871', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1112958', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113045', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113132', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113219', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113306', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113393', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113480', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113567', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113654', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113741', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113828', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1113915', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1114002', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1114089', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1114176', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1114263', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1114350', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.759 | Q16 | What Small molecule therapies have been approved by the FDA to treat androgenetic alopecia? | There are no drug Small molecule therapies approved to treat androgenetic alopecia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "androgenetic alopecia" OR LOWER(mesh_heading) = "androgenetic alopecia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.411 | Q16 | What Small molecule therapies have been approved by the FDA to treat Disorder of lipid metabolism? | There are no drug Small molecule therapies approved to treat Disorder of lipid metabolism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "disorder of lipid metabolism" OR LOWER(mesh_heading) = "disorder of lipid metabolism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1237 | Q16 | What Small molecule therapies have been approved by the FDA to treat lamellar ichthyosis? | There are no drug Small molecule therapies approved to treat lamellar ichthyosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lamellar ichthyosis" OR LOWER(mesh_heading) = "lamellar ichthyosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.256 | Q16 | What Protein therapies have been approved by the FDA to treat pituitary tumor? | There are no drug Protein therapies approved to treat pituitary tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pituitary tumor" OR LOWER(mesh_heading) = "pituitary tumor") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1243 | Q16 | What Small molecule therapies have been approved by the FDA to treat learning disability? | There are no drug Small molecule therapies approved to treat learning disability. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "learning disability" OR LOWER(mesh_heading) = "learning disability") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.706 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute megakaryoblastic leukaemia? | There are no drug Small molecule therapies approved to treat acute megakaryoblastic leukaemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute megakaryoblastic leukaemia" OR LOWER(mesh_heading) = "acute megakaryoblastic leukaemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.272 | Q16 | What Protein therapies have been approved by the FDA to treat prolymphocytic leukemia? | There are no drug Protein therapies approved to treat prolymphocytic leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prolymphocytic leukemia" OR LOWER(mesh_heading) = "prolymphocytic leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1369 | Q16 | What Small molecule therapies have been approved by the FDA to treat nervous system disease? | There are no drug Small molecule therapies approved to treat nervous system disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nervous system disease" OR LOWER(mesh_heading) = "nervous system disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.924 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic progressive multiple sclerosis? | Siponimod Fumarate is the only Small molecule therapy approved by the FDA to treat chronic progressive multiple sclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic progressive multiple sclerosis" OR LOWER(mesh_heading) = "chronic progressive multiple sclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1036784', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036787', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036790', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036793', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036796', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036799', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.163 | Q16 | What Protein therapies have been approved by the FDA to treat glaucoma? | There are no drug Protein therapies approved to treat glaucoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "glaucoma" OR LOWER(mesh_heading) = "glaucoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.235 | Q16 | What Protein therapies have been approved by the FDA to treat neuroendocrine carcinoma? | There are no drug Protein therapies approved to treat neuroendocrine carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroendocrine carcinoma" OR LOWER(mesh_heading) = "neuroendocrine carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1674 | Q16 | What Small molecule therapies have been approved by the FDA to treat synovial sarcoma? | There are no drug Small molecule therapies approved to treat synovial sarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "synovial sarcoma" OR LOWER(mesh_heading) = "synovial sarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.818 | Q16 | What Small molecule therapies have been approved by the FDA to treat bile duct carcinoma? | There are no drug Small molecule therapies approved to treat bile duct carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bile duct carcinoma" OR LOWER(mesh_heading) = "bile duct carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1282 | Q16 | What Small molecule therapies have been approved by the FDA to treat male reproductive organ cancer? | There are no drug Small molecule therapies approved to treat male reproductive organ cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "male reproductive organ cancer" OR LOWER(mesh_heading) = "male reproductive organ cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.571 | Q16 | What Small molecule therapies have been approved by the FDA to treat Noonan syndrome? | There are no drug Small molecule therapies approved to treat Noonan syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "noonan syndrome" OR LOWER(mesh_heading) = "noonan syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1092 | Q16 | What Small molecule therapies have been approved by the FDA to treat gangliosidosis? | There are no drug Small molecule therapies approved to treat gangliosidosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gangliosidosis" OR LOWER(mesh_heading) = "gangliosidosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.